查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654152

血液學癌症診斷市場規模、佔有率、趨勢分析報告：按產品、測試、最終用途、地區、細分預測，2025-2030 年

Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

血癌診斷市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球血液癌症診斷市場規模預計到2030年將達到160.4億美元，2025-2030年期間的複合年成長率為6.87%。

市場的成長受到白血病、淋巴瘤和骨髓瘤等骨髓惡性腫瘤發生率不斷上升的推動。此外，由於老年人口的增加，他們更容易患上包括血癌在內的慢性疾病，預計市場將大幅成長。此外，包括 NGS 和其他分子診斷技術在內的技術進步正在提高診斷的準確性和效率，這可能會在預測期內推動市場發展。

在過去的十年中，血癌診斷方法取得了巨大進展，其目的是為了降低日益上升的疾病發生率和死亡率。眾所周知，這些進步將提高早期癌症的檢測率，但目前已經取得了相當大的進展。例如，NGS可以分析癌細胞的整個基因組，了解基因突變，從而指南精準診斷和個人化治療。 2022 年 10 月，Sysmex 集團公司 OGT 宣布推出一系列新產品，以增強其不斷擴大的 NGS 產品組合。特別是，SureSeq Myeloid Plus 面板旨在識別與各種骨髓疾病相關的基因突變，增強公司在這一重要研究領域的能力。

分子成像技術，例如 SPECT/CT、PET 和流式細胞技術，利用分子造影劑檢測指示疾病不同階段的分子標記並有助於檢測和監測。成像技術的進步提高了準確性和早期檢測能力，從而推動了市場的發展。全球參與企業正在採用自動影像檢查和系統來增加市場佔有率。例如，2023年5月，Sysmex Corporation宣佈在日本推出其臨床流式細胞技術系統。系統包括XF-1600流式細胞儀、PS-10樣本製備系統、抗體試劑及其他相關產品。該系統可實現流式細胞技術檢測從樣品製備到測量結果報告的全過程自動化，有助於提高檢測的效率和標準化。

世界各國政府都意識到白血病和淋巴瘤等骨髓惡性腫瘤發生率的上升帶來的巨大醫療負擔。為了應對這種情況，許多國家推出了全面的國家癌症控制計劃，並優先考慮早期發現和篩檢工作。例如，美國癌症研究所最近推出了博·拜登癌症登月舉措，以加速癌症研究，使美國更容易獲得和負擔得起預防性篩檢。

市場的主要企業包括 Illumina、InVivoScribe、Ipsogen（Qiagen）、Asuragen（Bio-Techne）、Danaher Corporation、Abbott、SkylineDx、Adaptive Technologies 和 Bio-Rad Laboratories。這些公司正在推行各種策略舉措，包括產品發布和核准，以服務其全球客戶。例如，2023 年 9 月，Adaptive Technologies 開始 Epic 整合 clonoSEQ，這是一種用於血癌 MRD 監測的分子診斷測試。此整合將使醫療保健提供者能夠直接在 Epic 的 EHR 系統內訂購和審查 clonoSEQ 測試結果，從而簡化臨床決策並改善患者護理。

血液學癌症診斷市場報告重點

  • 根據產品，檢測試劑套件和試劑在 2024 年血液學癌症診斷市場中佔據最大的銷售佔有率。這一高佔有率是由用於檢測特定生物標記、基因突變和其他指標的檢測套件和試劑推動的，使醫療專業人員能夠更有效地診斷和治療疾病。
  • 根據測試，血液檢測領域佔據市場主導地位，在 2024 年佔據最大佔有率。這是由於用於檢測血癌的技術創新和血液檢測套組的可用性不斷提高。
  • 根據最終用途，醫院和診所佔據市場主導地位，在 2024 年佔據血液學癌症診斷市場的最大佔有率。這是因為法醫學和醫院醫學實驗室對疾病診斷、血球計數和血型分析的需求不斷增加。此外，醫院實驗室的發展對於滿足患者不斷變化的需求至關重要，越來越多的醫院希望在其環境中提供更廣泛的服務。
  • 北美白血病等慢性病發生率較高，需要定期監測和診斷檢測，對先進的診斷工具和技術的需求日益成長。
  • 預計在 2025-2030 年預測期內，亞太地區將以最快的速度成長。這得歸功於擁有創新設備製造能力和加速診斷研究能力的製造商的存在。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章血液癌症診斷市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 血癌診斷市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析

第 4 章血液癌症診斷市場：按產品分類的估計和趨勢分析

  • 細分儀表板
  • 血液癌症診斷市場：產品變異分析
  • 2018-2030 年市場規模、預測及趨勢分析
  • 裝置
  • 檢測套件和試劑

第 5 章。

  • 2024 年和 2030 年的測試市場佔有率
  • 細分儀表板
  • 透過測試展望全球血癌診斷市場
  • 2018-2030 年市場規模、預測及趨勢分析
  • 血液檢查
  • 影像檢查
  • 切片檢查
  • 分子檢測

第 6 章血液學癌症診斷市場：按最終用途的估計和趨勢分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 細分儀表板
  • 全球血液癌症診斷市場前景（依最終用途）
  • 2018-2030 年市場規模、預測及趨勢分析
  • 醫院和診所
  • 診斷實驗室
  • 研究所

第 7 章血癌診斷市場：按地區分類的估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模、預測趨勢分析，2018-2030
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • 2024 年主要企業的市場佔有率分析
    • Illumina
    • InVivoScribe
    • Ipsogen（Qiagen）
    • Asuragen（Bio-Techne）
    • Danaher Corporation
    • Abbott
    • Sequenta（Adaptive bIoTechnologies）
    • SkylineDx
    • Bio-Rad Laboratories
    • Alercell
    • Sophia Genetics
Product Code: GVR-4-68040-330-3

Blood Cancer Diagnostics Market Growth & Trends:

The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company's capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.

Blood Cancer Diagnostics Market Report Highlights:

  • Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2024. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively
  • Based on tests, blood tests segment dominated the market and accounted for the largest share in 2024. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection
  • Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2024. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings
  • North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies
  • Asia Pacific is expected to witness the fastest growth over the forecast period from 2025 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Test
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Test outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of blood cancer
      • 3.2.1.2. Increasing R&D and clinical trials
      • 3.2.1.3. Advancements in diagnostics technologies
      • 3.2.1.4. Rising government initiatives and regulatory support
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High development cost and accessibility barriers
  • 3.3. Blood Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Blood Cancer Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Blood Cancer Diagnostics Market: Product Movement Analysis
  • 4.3. Blood Cancer Diagnostics Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Assay Kits and Reagents
    • 4.5.1. Assay Kits and Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Blood Cancer Diagnostics Market: Test Estimates & Trend Analysis

  • 5.1. Test Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Blood Cancer Diagnostics Market by Test Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Blood Tests
    • 5.5.1. Blood Tests Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Imaging Tests
    • 5.6.1. Imaging Tests Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Biopsy
    • 5.7.1. Biopsy Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Molecular Test
    • 5.8.1. Molecular Tests Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Blood Cancer Diagnostics Market: End-use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Blood Cancer Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals and Clinics
    • 6.5.1. Hospitals and Clinics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Diagnostic Labs
    • 6.6.1. Diagnostic Labs Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Research Institutes
    • 6.7.1. Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Blood Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/Reimbursement
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/Reimbursement
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/Reimbursement
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/Reimbursement
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/Reimbursement
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/Reimbursement
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/Reimbursement
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/Reimbursement
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/Reimbursement
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/Reimbursement
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/Reimbursement
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/Reimbursement
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/Reimbursement
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/Reimbursement
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/Reimbursement
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/Reimbursement
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/Reimbursement
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/Reimbursement
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/Reimbursement
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/Reimbursement
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/Reimbursement
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/Reimbursement
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Illumina
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Services benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. InVivoScribe
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Services benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Ipsogen (Qiagen)
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Services benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Asuragen(Bio-Techne)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Services benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Danaher Corporation
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Services benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Abbott
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Services benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Sequenta (Adaptive biotechnologies)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Services benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. SkylineDx
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Services benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Bio-Rad Laboratories
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Services benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Alercell
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Services benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Sophia Genetics
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Services benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 5 North America blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 8 U.S. blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 11 Canada blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Mexico blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 13 Mexico blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 14 Mexico blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 18 Europe blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Germany blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 20 Germany blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 21 Germany blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 UK blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 23 UK blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 24 UK blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 25 France blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 26 France blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 27 France blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Italy blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 29 Italy blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 30 Italy blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Spain blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 32 Spain blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 33 Spain blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Denmark blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 35 Denmark blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 36 Denmark blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Sweden blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 38 Sweden blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 39 Sweden blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Norway blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 41 Norway blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 42 Norway blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 48 China blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 49 China blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Japan blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 51 Japan blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 52 Japan blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 53 India blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 54 India blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 55 India blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 56 South Korea blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 57 South Korea blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 58 South Korea blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Australia blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 60 Australia blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 61 Australia blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Thailand blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 63 Thailand blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 64 Thailand blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 66 Latin America blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 67 Latin America blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Brazil blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 69 Brazil blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 70 Brazil blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 71 Argentina blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 72 Argentina blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 73 Argentina blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 74 MEA blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 76 MEA blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 77 MEA blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 78 South Africa blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Africa blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 80 South Africa blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 84 UAE blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 85 UAE blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 86 UAE blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 87 Kuwait blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 89 Kuwait blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Blood cancer diagnostics market: market outlook
  • Fig. 14 Blood cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Blood cancer diagnostics market driver impact
  • Fig. 20 Blood cancer diagnostics market restraint impact
  • Fig. 21 Blood cancer diagnostics market strategic initiatives analysis
  • Fig. 22 Blood cancer diagnostics market: Product movement analysis
  • Fig. 23 Blood cancer diagnostics market: Product outlook and key takeaways
  • Fig. 24 Instruments estimates and forecast, 2018 - 2030
  • Fig. 25 Assay kits and reagents market estimates and forecast, 2018 - 2030
  • Fig. 26 Blood cancer diagnostics Market: Test movement analysis
  • Fig. 27 Blood cancer diagnostics market: Test outlook and key takeaways
  • Fig. 28 Blood tests market estimates and forecasts, 2018 - 2030
  • Fig. 29 Imaging tests market estimates and forecasts,2018 - 2030
  • Fig. 30 Biopsy market estimates and forecasts,2018 - 2030
  • Fig. 31 Molecular tests market estimates and forecasts,2018 - 2030
  • Fig. 32 Blood cancer diagnostics market: End-use movement analysis
  • Fig. 33 Blood cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 34 Hospitals and clinics market estimates and forecasts, 2018 - 2030
  • Fig. 35 Diagnostic labs market estimates and forecasts,2018 - 2030
  • Fig. 36 Research institutes market estimates and forecasts, 2018 - 2030
  • Fig. 37 Global blood cancer diagnostics market: Regional movement analysis
  • Fig. 38 Global blood cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 39 Global blood cancer diagnostics market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America, by country
  • Fig. 46 North America
  • Fig. 47 North America market estimates and forecasts, 2018 - 2030
  • Fig. 48 U.S. key country dynamics
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada country dynamics
  • Fig. 51 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 52 Mexico country dynamics
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 54 Europe
  • Fig. 55 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 56 UK country dynamics
  • Fig. 57 UK market estimates and forecasts, 2018 - 2030
  • Fig. 58 Germany
  • Fig. 59 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 60 France country dynamics
  • Fig. 61 France market estimates and forecasts, 2018 - 2030
  • Fig. 62 Italy country dynamics
  • Fig. 63 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 64 Spain country dynamics
  • Fig. 65 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 66 Denmark country dynamics
  • Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 68 Sweden country dynamics
  • Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 70 Norway country dynamics
  • Fig. 71 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 72 Asia Pacific
  • Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 74 China country dynamics
  • Fig. 75 China market estimates and forecasts, 2018 - 2030
  • Fig. 76 Japan country dynamics
  • Fig. 77 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 78 India country dynamics
  • Fig. 79 India market estimates and forecasts, 2018 - 2030
  • Fig. 80 Thailand country dynamics
  • Fig. 81 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 82 South Korea country dynamics
  • Fig. 83 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 84 Australia country dynamics
  • Fig. 85 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 86 Latin America
  • Fig. 87 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 88 Brazil country dynamics
  • Fig. 89 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 90 Argentina country dynamics
  • Fig. 91 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 92 Middle East and Africa
  • Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 South Africa country dynamics
  • Fig. 95 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 96 Saudi Arabia country dynamics
  • Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 98 UAE country dynamics
  • Fig. 99 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 100 Kuwait country dynamics
  • Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 102 Market share of key market players- Blood cancer diagnostics market, 2024
  • Fig. 103 Company Categorization